author-photo

Cristian Massacesi

Novartis

72

Papers

3084

Citations

Citation Trend

Filter By

Papers (55) Sort By

Journal Conference Others

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

2018 Breast Cancer Research and Treatment
Show All
- Source
- Cite
- Save
Citations (26)
Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM).

2017 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (5)
Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

2017 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (289)
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial

2017 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (312)
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

2017 The Lancet
Show All
- Source
- Cite
- Save
Citations (572)
Abstract S6-01: PIK3CA status in circulating tumor DNA (ctDNA) predicts efficacy of buparlisib (BUP) plus fulvestrant (FULV) in postmenopausal women with endocrine-resistant HR+/HER2– advanced breast cancer (BC): First results from the randomized, phase III BELLE-2 trial

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (79)
A randomized adaptive phase II/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2– advanced breast cancer (BELLE-4)

2016 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (87)
A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours

2016 Anticancer Research
Show All
- Source
- Cite
- Save
Citations (59)
Abstract A02: Biomarkers of drug response to buparlisib: Results of next-generation sequencing in a phase II trial of advanced endometrial carcinoma

2015 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
BELLE-3: A Phase III study of the pan-phosphatidylinositol 3-kinase (PI3K) inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2- locally advanced/metastatic breast cancer (BC) pretreated with aromatase inhibitors (AIs) and refractory to mTOR inhibitor (mTORi)-based treatment.

2015 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)